Medtronic Inc. Stock Buy Recommendation Reiterated (MDT)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (TheStreet) -- Medtronic (NYSE:MDT) has been reiterated by TheStreet Ratings as a buy with a ratings score of B . The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Highlights from the ratings report include:

• MDT's revenue growth has slightly outpaced the industry average of 5.8%. Since the same quarter one year prior, revenues slightly increased by 1.6%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
• The stock has risen over the past year as investors have generally rewarded the company for its earnings growth and other positive factors like the ones we have cited in this report. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
• MEDTRONIC INC has improved earnings per share by 7.8% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, MEDTRONIC INC increased its bottom line by earning $3.24 versus $2.83 in the prior year. This year, the market expects an improvement in earnings ($3.65 versus $3.24).
• The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry average. The net income increased by 5.2% when compared to the same quarter one year prior, going from $821.00 million to $864.00 million.
• The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, MEDTRONIC INC's return on equity exceeds that of both the industry average and the S&P 500.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company has a P/E ratio of 12.7, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Medtronic has a market cap of $42.49 billion and is part of the health care sector and health services industry. Shares are up 8.9% year to date as of the close of trading on Thursday.

You can view the full Medtronic Ratings Report or get investment ideas from our investment research center.

--Written by a member of TheStreet Ratings Staff.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free Download Now

For more information on Medtronic Inc. click any of the following:

• Medtronic Inc. Stock Price

• Medtronic Inc. Analyst Ratings

• Medtronic Inc. Key Stats & Profile

• Medtronic Inc. Earnings

• Medtronic Inc. Ratio Comparison

• Medtronic Inc. Growth Rates

• Medtronic Inc. Balance Sheet

• Medtronic Inc. Cash Flow

• Medtronic Inc. Income Statement